Search: onr:"swepub:oai:lup.lub.lu.se:6931d0c7-69c9-4f45-8319-a19187005607" > International myelo...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04654naa a2200865 4500 | |
001 | oai:lup.lub.lu.se:6931d0c7-69c9-4f45-8319-a19187005607 | |
003 | SwePub | |
008 | 160401s2009 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:119499071 | |
024 | 7 | a https://lup.lub.lu.se/record/15062192 URI |
024 | 7 | a https://doi.org/10.1038/leu.2009.1272 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1194990712 URI |
040 | a (SwePub)lud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Giralt, S.4 aut |
245 | 1 0 | a International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) |
264 | c 2009-06-25 | |
264 | 1 | b Springer Science and Business Media LLC,c 2009 |
520 | a Multiple myeloma is the most common indication for high-dose chemotherapy with autologous stem cell support (ASCT) in North America today. Stem cell procurement for ASCT has most commonly been performed with stem cell mobilization using colony-stimulating factors with or without prior chemotherapy. The target CD34+ cell dose to be collected as well as the number of apheresis performed varies throughout the country, but a minimum of 2 million CD34+ cells/kg has been traditionally used for the support of one cycle of high-dose therapy. With the advent of plerixafor (AMD3100) (a novel stem cell mobilization agent), it is pertinent to review the current status of stem cell mobilization for myeloma as well as the role of autologous stem cell transplantation in this disease. On June 1, 2008, a panel of experts was convened by the International Myeloma Foundation to address issues regarding stem cell mobilization and autologous transplantation in myeloma in the context of new therapies. The panel was asked to discuss a variety of issues regarding stem cell collection and transplantation in myeloma especially with the arrival of plerixafor. Herein, is a summary of their deliberations and conclusions. Leukemia (2009) 23, 1904-1912; doi: 10.1038/leu.2009.127; published online 25 June 2009 | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a high-dose therapy | |
653 | a stem cell collection | |
653 | a myeloma | |
653 | a plerixafor | |
653 | a IMWG | |
653 | a guidelines | |
700 | 1 | a Stadtmauer, E. A.4 aut |
700 | 1 | a Harousseau, J. L.4 aut |
700 | 1 | a Palumbo, A.4 aut |
700 | 1 | a Bensinger, W.4 aut |
700 | 1 | a Comenzo, R. L.4 aut |
700 | 1 | a Kumar, S.4 aut |
700 | 1 | a Munshi, N. C.4 aut |
700 | 1 | a Dispenzieri, A.4 aut |
700 | 1 | a Kyle, R.4 aut |
700 | 1 | a Merlini, G.4 aut |
700 | 1 | a San Miguel, J.4 aut |
700 | 1 | a Ludwig, H.4 aut |
700 | 1 | a Hajek, R.4 aut |
700 | 1 | a Jagannath, S.4 aut |
700 | 1 | a Blade, J.4 aut |
700 | 1 | a Lonial, S.4 aut |
700 | 1 | a Dimopoulos, M. A.4 aut |
700 | 1 | a Einsele, H.4 aut |
700 | 1 | a Barlogie, B.4 aut |
700 | 1 | a Anderson, K. C.4 aut |
700 | 1 | a Gertz, M.4 aut |
700 | 1 | a Attal, M.4 aut |
700 | 1 | a Tosi, P.4 aut |
700 | 1 | a Sonneveld, P.4 aut |
700 | 1 | a Boccadoro, M.4 aut |
700 | 1 | a Morgan, G.4 aut |
700 | 1 | a Sezer, O.4 aut |
700 | 1 | a Mateos, M. V.4 aut |
700 | 1 | a Cavo, M.4 aut |
700 | 1 | a Joshua, D.4 aut |
700 | 1 | a Turesson, Ingemaru Lund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine4 aut0 (Swepub:lu)medf-itu |
700 | 1 | a Chen, W.4 aut |
700 | 1 | a Shimizu, K.4 aut |
700 | 1 | a Powles, R.4 aut |
700 | 1 | a Richardson, P. G.4 aut |
700 | 1 | a Niesvizky, R.4 aut |
700 | 1 | a Rajkumar, S. V.4 aut |
700 | 1 | a Durie, B. G. M.4 aut |
710 | 2 | a Institutionen för kliniska vetenskaper, Malmöb Medicinska fakulteten4 org |
773 | 0 | t Leukemiad : Springer Science and Business Media LLCg 23:10, s. 1904-1912q 23:10<1904-1912x 1476-5551x 0887-6924 |
856 | 4 | u http://dx.doi.org/10.1038/leu.2009.127y FULLTEXT |
856 | 4 | u https://www.nature.com/articles/leu2009127.pdf |
856 | 4 8 | u https://lup.lub.lu.se/record/1506219 |
856 | 4 8 | u https://doi.org/10.1038/leu.2009.127 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:119499071 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.